Minireviews
Copyright ©The Author(s) 2024.
World J Hepatol. Oct 27, 2024; 16(10): 1158-1168
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1158
Figure 1
Figure 1 The treatment methods for liver cancer are constantly advancing, evolving from surgery to systematic treatment[85-88]. HCC: Hepatocellular carcinoma; TACE: Transartical chemoembolization.
Figure 2
Figure 2 Mechanisms of programmed cell death 1/programmed cell death ligand 1 axis in hepatocellular carcinoma. HCC: Hepatocellular carcinoma; TCR: T cell receptor; PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand 1; MDSC: Myeloid derived suppressive cell.
Figure 3
Figure 3 Immunotherapy-based combination therapy for liver cancer. TACE: Transartical chemoembolization.